FOUR WAYS TO REMAIN VIGILANT ABOUT COVID-19
RENEWED COMMITMENT TO GAVI, THE VACCINE ALLIANCE
Perspectives on COVID-19 from Mace Rothenberg, M.D.
PARTNERING WITH DIRECT RELIEF TO PROVIDE COVID-19 SUPPLIES TO HOSPITALS
Age: Addressing a Blind Spot in Cancer Care
Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020 Pfizer Inc . (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). BNT162b1 and…